TABLE 2.

Summary Results of OS by Ascites Status in Entire Cohort Within Patients Who Had Local Disease and Metastatic Disease and Within Patients Who Had Resectable Disease, BR Disease, and LAUR Disease

			OS Estimates, Probability (95% CI)
Cohort	No.	Median OS, mo	1 y	2 y	3 y	cHR (95% CI)	P
A1: Entire cohort
No ascites	154	15.2	0.59 (0.52–0.67)	0.30 (0.24–0.38)	0.12 (0.08–0.18)	1
Ascites	154	10.2	0.42 (0.35–0.51)	0.17 (0.12–0.25)	0.07 (0.03–0.13)	1.58 (1.23–2.03)	<0.001
A2: Local disease
No ascites	94	18.6	0.71 (0.63–0.81)	0.38 (0.29–0.49)	0.16 (0.10–0.26)	1
Ascites	94	13.6	0.53 (0.43–0.64)	0.23 (0.15–0.34)	0.09 (0.04–0.18)	1.62 (1.18–2.24)	0.003
A3: Metastatic disease
No ascites	60	10.4	0.40 (0.29–0.55)	0.18 (0.10–0.31)	0.05 (0.01–0.16)	1
Ascites	60	7.8	0.27 (0.18–0.41)	0.09 (0.04–0.21)	0.04 (0.01–0.14)	1.35 (0.92–1.98)	0.12
B1: Resectable disease
No ascites	24	20.3	0.71 (0.55–0.92)	0.38 (0.22–0.63)	0.17 (0.07–0.41)	1
Ascites	24	14.5	0.58 (0.42–0.82)	0.22 (0.10–0.49)	0.11 (0.03–0.39)	1.54 (0.82–2.91)	0.18
B2: BR disease
No ascites	19	20.6	0.79 (0.63–1)	0.46 (0.28–0.76)	0.29 (0.14–0.60)	1
Ascites	19	16.0	0.79 (0.63–1)	0.27 (0.12–0.59)	0	1.82 (0.87–3.77)	0.11
B3: LAUR disease
No ascites	51	17.6	0.69 (0.57–0.83)	0.35 (0.24–0.51)	0.11 (0.05–0.25)	1
Ascites	51	11.3	0.40 (0.28–0.56)	0.21 (0.12–0.37)	0.11 (0.05–0.27)	1.63 (1.06–2.51)	0.03